Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04317534 |
|
Recruitment Status :
Recruiting
First Posted : March 23, 2020
Last Update Posted : December 13, 2022
|
Sponsor:
Greg Durm, MD
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Greg Durm, MD, Big Ten Cancer Research Consortium
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 2025 |
| Estimated Study Completion Date : | April 2026 |